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Abstract:  
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that causes the 
new Coronavirus disease (COVID-19). The symptoms range from mild to severe with a higher 
incidence of severe cases seen in patients with risk factors such as older age and comorbidities. 
COVID-19 is mainly spread through the inhalation of respiratory droplets from coughing or sneezing 
or via contact with droplet-contaminated surfaces. Paramedics should be aware that some aerosol 
generating procedures (AGPs) may put them at a higher risk of contracting the virus via possible 
airborne transmission. The use of remote triage clinical assessment is likely to increase as a result of 
the pandemic. There is no curative drug treatment for the virus and some medications may 
exacerbate its effects or make patients more susceptible to it. Paramedics should accept that feeling 
stressed by the pandemic is a natural response. Official guidelines and advice are evolving 
continually as the evidence on SARS-CoV-2 and COVID-19 grows. Paramedics should keep up to date 
with the latest clinical guidance from their employers.  
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COIVID-19: What do we know so far?  
Introduction  
In late December 2019, a novel coronavirus was identified in Chinese City of Wuhan, causing severe 
respiratory disease including pneumonia [1]. In January 2020, the World Health Organisation (WHO) 
named this novel coronavirus as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and 
the associated disease as COVID-19 [1-3].  The first confirmed case of COVID-19 in the UK was 
recorded on the 31st January 2020 [4] and the number of cases continues to rise since then (Figure 
1).  
Similar to other coronaviruses that have infected humans, SARS-CoV-2 are enveloped, positive-
sense, single stranded RNA viruses that cause respiratory infections [5, 6]. As per most human 
coronavirus infection, most SARS-CoV-2 infections induce mild respiratory disease and symptoms [7, 
8].  
Epidemiology 
As of 7th April 2020, there are over 1,270,000 cases of COVID-19 diagnosed worldwide with over 
68,000 confirmed fatality [9]. In UK, there are a cumulative total of over 60,000 confirmed cases and 
resulted in 7,097 COVID-19 related deaths [10].   
 
Figure 1: UK COVID-19 cases and deaths on 7th April 2020   Source: DHSC & PHE  
It is estimated that around 5 -10% admitted patients would become critically unwell and may require 
respiratory support in intensive care/ therapy units [11, 12].  
Furthermore, the estimated basic reproduction number (R0) was around 2-2.5 [13, 14] in early April 
2020 which means a COVID-19 case could infect an average 2-2.5 people in a population where 
everyone is susceptible who does not have specific immunity against it [15].  
COVID-19 has an estimated median incubation period of 4–6 days. Of those who develop symptoms, 
97.5% will do so within 11.5 days [2, 5, 11, 13, 14, 16]. Most patients will not be infectious until the 
onset of symptoms and their infectiousness depends on the severity of their symptoms and stage of 
their illness. However, due to the inter-individual variations in the length of incubation period, some 
infected individuals could be infectious before symptoms are developed and there are reported 
cases of asymptomatic transmission.[5, 17].  
Infection prevention and control (including Personal Protective Equipment) 
Standard infection control precautions (SIPCs) and transmission based precautions (TBPs) must be 
used when managing patients with suspected or confirmed COVID-19. SICPs are the universal 
precautions that should be applied by paramedics routinely to minimise the risks relating to the 
transmission of infections from all human body fluids secretions and excretions. In contrast, TBPs are 
additional infection control precautions as SIPCs alone are inefficient in preventing the cross 
transmission of COVID-19 [18]. 
From the information that is available regarding SARS-COV-2 viruses, it is believe that they have 
similar route of transmission to SARS-CoV-1 and MERS-CoV, this is through respiratory droplets 
(>5µm) which are produced when an infected person coughs or sneezes. These droplets can be 
inhaled into the lungs by people nearby or could land on surfaces where the viruses could survive for 
a period of time and could then infect others in contact with the contaminated surfaces [18].  
However, SARS-CoV-2 can be isolated in the gastrointestinal tract, saliva, and urine, these routes of 
potential transmission could not be ruled out at this time [11, 19]. 
In addition, some medical and patient care procedures (known as aerosol generating procedures- 
AGPs) could generate airborne particles contaminated by known infectious substances (aerosols) 
which are less than 5 micrometres (µm) in size[20]. These aerosols can remain suspended in the air, 
travel over a distance and may cause infection if they are inhaled. AGPs could be linked to a 
significantly increased risk of healthcare workers contracting SARS-Cov-1 during the previous SARS 
outbreak in 2003 [21]. Furthermore, there is recent evidence to demonstrate that SARS-CoV-2 has 
similar properties to the SARS-CoV-1 which remains viable in aerosol form (≤5μm) [22]. This would 
suggest COVID-19 could be airborne during AGPs.    
A systematic review by Tran and colleagues[23] had summarised the risks of SARS transmissions in 
healthcare workers when carrying out different aerosol generating procedures. This informed the 
New and Emerging Respiratory Virus Threats Advisory Group’s (NERVTAG) decision on which 
procedures are included on the list of AGPs for the UK. Some of the common AGPs conducted in the 
pre-hospital care settings include some procedures related to cardiopulmonary resuscitation e.g. 
Advanced airway procedures-laryngoscopy, intubation, extubation, surgical airway; Manual 
ventilation; Suctioning; Management of Choking, Foreign body airway obstruction removal[24].  
It is worth noting that even though nebulisation itself is an aerosol generating procedures, the 
evidence suggested the aerosol does not contain any viruses and minimal viable bacteria were 
recovered[25]. During nebulisation, the aerosol derives from a non-patient source (the fluid in the 
nebuliser chamber) and does not carry patient-derived viral particles. If a particle in the aerosol 
coalesces with a contaminated mucous membrane, it will cease to be airborne and therefore will not 
be part of an aerosol. Staff should use appropriate hand hygiene when helping patients to remove 
nebulisers and oxygen masks.  
A Canadian study recommended the use of metered dose inhaler of bronchodilators if available to 
minimise the theoretical risk of viral aerosolization from nebulisation[26].  
With an increased level of COVID-19 in the community and the UK is entering the sustained 
transmission phase of the pandemic in early April 2020, Public Health England recommended two 
levels of personal protective equipment for the Ambulance sector[24] (Figure 2 & Figure 3)Figure 2: 
Level 2 and 3 PPE with respiratory hood:  
Level 2: All ambulance attendances regardless of patient symptoms 
• Disposable gloves 
• Disposable apron 
• Fluid repellent surgical mask 
• Eye protection  
Level 3: Aerosol generating procedures to be carried out 
• Disposable gloves 
• Fluid repellent coveralls 
• FFP3 or powered respirator hood 
• Eye protection 
 
Figure 2: Level 2 and 3 PPE with respiratory hood   Credit: James Fox  
 
 
Figure 3: Level 2 and 3 PPE with facemasks   Credit: James Fox  
Clinical Assessment of suspected/ confirmed COVID-19 patients 
Fever (>37.8°C), cough and myalgia or fatigue are the three most common symptoms presented in 
patients who are infected with SARS-Cov-2 [2, 5, 7, 8, 11].  Other less common symptoms include 
sputum production, sore throat, headache, haemoptysis and diarrhoea [7, 8]. 
The current possible case definition of COVID-19 (as of 13 March 2020) in the UK [27] is as follows:  
Patients required hospital admission (as decided by a hospital practitioner with an expectation 
that the patient will need to stay at least one night) and have either: 
• Clinical or radiological evidence of pneumonia 
• Acute respiratory distress syndrome 
• Influenza like illness (fever ≥37.8°C and at least one of the following respiratory symptoms, 
which must be of acute onset: persistent cough (with or without sputum), hoarseness, nasal 
discharge or congestion, shortness of breath, sore throat, wheezing, sneezing). 
In addition, paramedics are advised that COVID-19 infection should be considered in all cases of 
respiratory infection in the pre-hospital emergency care settings [24]. If patients meet the below 
criteria they are to be classified as a possible or confirmed case. 
• Acute respiratory distress syndrome  
Or 
• High temperature (of 37.8°C or higher) 
 
• And at least one of the following which must be of acute onset: 
o Persistent cough (with or without sputum), hoarseness, nasal discharge or 
congestion, shortness of breath, sore throat, wheezing or sneezing 
 
Older people (>60 years), men, patients with underlying chronic diseases (such as respiratory 
diseases, hypertension, diabetes) or comorbidities resulting in weaker immune functions are all 
linked to increased risks of developing severe illness from COVID-19 [5, 8, 11].   
Paramedics should use existing thresholds for vital signs and early warning score (such as NEWS2 
score/ POP score etc.) to guide their management of suspected/ confirmed COVID-19 patients, as 
abnormal vital signs such as increased respiratory rate, increased pulse rate and low oxygen 
saturation (<93%) on air were linked to increase morbidity and mortality in reported cases [2].  
In addition, Paramedics should be mindful that both adult and child death are increasing from a non 
COVID-19 related diseases. This could be related to people’s fear and often delay presenting to 
healthcare because they perceive a higher risk of contracting COVID-19 if they attend healthcare 
facilities.  
Patients who are well enough to remain in the community with new continuous cough and/or fever 
(>37.8°C) should be advised to stay at home for self-isolation and their family should be advised to 
be self-isolating for 14 days as per current government advice [28].  Additional advice for those who 
are in self-isolation including:  
• Stay in a well-ventilated room, use a separate bathroom if available; if they have to share 
the bathroom clean it regularly, use separate towels, wear a clean mask when using a 
communal kitchen, use separate crockery and cutlery 
• Wash hands with soap and water before cooking and eating and after using the toilet 
• Have food, medication, and supplies delivered to you 
• Double bag and seal all waste. These bags should be tied securely and kept separate from 
other waste. This should be put aside for at least 72 hours before being put in your usual 
external household waste bin. 
• Seek prompt medical attention if their illness or the illness in any household members is 
worsening. If it’s not an emergency, contact NHS 111 online. If they have no internet access, 
they should call NHS 111. If it is an emergency (such as reduced level of consciousness, acute 
shortness of breath, cyanosis etc.) and they need to call an ambulance, dial 999 and inform 
the call handler or operator that they or their relative have coronavirus symptoms. 
Remote telephone clinical assessment of suspected/ confirmed COVID-19 patients  
At a time where much of the world is having to adapt to working remotely and is having to embrace 
the use of technology more in their personal lives; so are paramedics in their professional lives. 
Telephone triage, also known as remote clinical decision making (RCDM), has long been a well-
recognised and an increasingly used method of managing a growing demand on the ambulance and 
primary care services [29]. Such services, along with advice and referral-based service (NHS 111, NHS 
24, and NHS Direct) have seen a rapid and significant increase in call volume in response to COVID-
19 [30]. 
Guidance released from NHS England and NHS Improvement [31] suggests that in response to 
COVID-19 healthcare providers should roll out remote consultations using video, telephone, email 
and text message services for all important routine activity as soon as possible. In addition to this, 
they also ask that clinical staff themselves, where possible, work from home and consider how they 
can use telephone-based or digital / video-based consultations and advice for patients. 
RCDM is fast becoming a recognised speciality in clinical practice and multiple professional career 
frameworks. This practice is normally underpinned by significant post registration experience, 
bespoke training and more recently specific RCDM higher education [29].  The impact of the 
significant increase in COVID-19 call volume when coupled with guidelines such those mentioned 
earlier has meant that RCDM has become something upon which a range of clinicians have had little 
choice but to rely on entirely to carry out an increasing amount of their practice; with a lack of 
experience, training, and specialist education, and in home office environments away from 
traditional support mechanisms. 
Those staff currently working in telephone triage will be well adept to practising remotely, and 
various clinical decision support software tools currently being used have activated their pandemic 
flu algorithms to support such clinicians more in their assessment; in addition to changing demand 
management processes. Experienced RCDM staff are maintaining capacity and following public 
health guidance by utilising home working packages with the use of digital phone systems and 
remote computer-aided dispatch modules. Additional video-based platforms have been rapidly 
rolled out to augment this method of remote practice further and reduce some risk. Increased surge 
capacity can also be realised from these homeworking triage staff through the use of ad hoc 
overtime in response to spikes in call demand and by freeing up space in clinical hub estates for 
newer staff who require more intensive support and guidance. 
Many clinicians, however, favour not to practice over the phone and for some it will not be possible 
at all. While there is evidence that suggests telephone triage is generally safe in a normal cohort of 
general medical patients [32], the risks associated with non-face-to-face clinical practice are also 
well known and explored [33]. Telephone triage clinicians can assess and manage an estimated 3-4 
patients per hour. In contrast, ambulance-based clinicians may only see one patient during this time. 
Many services are looking to redeploy clinical staff, recruit new temporary staff, utilise military 
medical support, and more readily use agency staff to provide this remote assessment of patients to 
help with managing an overwhelming COVID-19 based demand. 
To support clinicians new to working in this specialised area of clinical practice, the Royal College of 
General Practitioners [34] have released guidance on conducting telephone consultations; which 
while helpful, provides little more than generic assessment and communication types adapted 
somewhat for remote practice. Greenhalgh et al. [35] however, provide a more robust case study 
approach to the remote management of covid19 patients in an article entitled ‘COVID-19: a remote 
assessment in primary care'. This article presents the guiding principles to remote assessment by 
phone or video and provides a call structure consistent with other widely recognised tools. Those 
clinicians finding themselves new to remote practice should review this piece and others relevant 
articles.  
While telephone triage was once an additional method of managing demand, it has, in response to 
COVID-19, become a method of managing the majority of demand; and will do so more as call 
volume increases. As a result, it must now be asked if the response to COVID-19 has created a 
context in which the face to face clinical consultation model has irrevocably been questioned; and 
telephone / remote triage and assessment becomes the primary method of future clinical practice. 
Use of Medicines in COVID-19 patients  
Supportive management is key with no medicines yet approved for the treatment of COVID-19 but a 
number currently undergoing clinical trials including within the United Kingdom.[36] 
It has been suggested that the use of Angiotensin Converting Enzymes Inhibitors (ACEIs) and 
Angiotensin Receptor Blockers (ARBs) may increase the likelihood or severity of COVID-19 [37]. This 
hypothesis is based on the theories that ACE-2 facilitates the entry of SARS-CoV-2 and that 
ACEIs/ARBs have the potential to upregulate ACE2 as observed in animal studies but with no 
consistent evidence from human data [38]. 
There is no evidence available to support the routine discontinuation of ACEIs or ARBs. Paramedics 
should encourage patients to continue their prescribed medications unless specifically advised to 
stop by their medical team [39, 40]. 
Paramedics with prescribing responsibilities should consider whether the ACEI or ARB are prescribed 
for current or long-term benefits. If the prescribing of ACEIs/ARBs is for current benefits (such as 
severe uncontrolled hypertension or heart failure), stopping these medications may lead to a rapid 
deterioration. For those patients who are taking ACEIs/ ARBs for long-term benefits, precautionary 
principles should be applied including withholding ACEIs/ARBs during acute infection which could 
reduce the theoretical short-term risks during acute infection [41]. It may be beneficial to ask the 
patient to contact the original prescriber or their own general practitioner for further information.  
Paramedics are advised to continue with their existing pre-hospital emergency care drug 
interventions as indicated as there is no current evidence to suggest the appropriate use of 
intravenous fluids or glyceryl trinitrate (GTN) is linked to worsening conditions in COVID-19 patients. 
The media reported that the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) could worsen 
COVID-19 due to the theoretical risk of ibuprofen increasing the expression of ACE-2 although this 
has only been shown in animal studies as above [37, 42]. Known NSAID effects including reduced 
inflammation or fluid retention may also contribute to the pneumonia seen in severe cases [27]. A 
recent systematic review found no published evidence for or against the use of NSAIDs in COVID-19 
patients [43]. 
Paramedics should take a cautionary approach by avoiding using NSAIDs as the first-line option for 
managing the symptoms of COVID-19 as recommended by UK guidance [44]. However, if patients 
are prescribed NSAIDs for existing conditions, they should continue these as directed by their 
healthcare professional [44, 45]. While NSAIDs, ACEIs or ARBs should not be discontinued routinely 
due to COVID-19 this may be recommended in patients who become acutely unwell due to the risk 
of acute kidney injury [46].  
Resuscitations in suspected/ confirmed COVID-19 patients  
Resuscitation Council UK (RCUK) have published resuscitation guidelines for healthcare professional 
managing patients with COVID-19 or suspected patients with COVID-19 [47]. The current guidelines 
for advanced life support for COVID-19 patients is in Figure 4.  
 
Figure 4: Adult Advanced Life Support for COVID-19 patients Used with kind permission from Resuscitation Council (UK) 
The RCUK guidelines are not specific to pre-hospital care but are adapted and applicable within the 
remit of the healthcare provider [47]. RCUK suggests that applying defibrillator pads during a cardiac 
arrest procedure can be done without PPE as “it may negate the need for chest compressions” [47]; 
once the defibrillator has been attached and used if appropriate, the rest of the team, where 
applicable, can put on the appropriate level 3 PPE as per the advice discussed above. RCUK [47] 
emphasise the importance of decision-making processes prior to the time of cardiac arrest and 
whether to commence CPR, however, this is not always possible in the pre-hospital environment.  
Once the initial patient assessment has been made and the patient has a shockable rhythm, up to 3 
shocks is recommended [48]. This is specifically for the use of manual defibrillators. RCUK 
recommend giving the first shock as usual, then reassess the rhythm after the first shock [48]. If the 
patient remains in a shockable rhythm, apply a further shock. If there is a potential perfusing 
rhythm, check for a pulse. If the patient has now moved to an non-shockable rhythm, start chest 
compressions with the appropriate PPE [48]. 
RCUK’s current guidelines state that rhythm assessment and defibrillation are not aerosol-
generating procedures (AGPs); However, initiating cardio-pulmonary resuscitation (CPR) is 
considered to be AGP. Also note that the post-resuscitation care recommends an oxygen saturation 
level of 94-98% due to acute lung injury and aspiration induced lung injury caused by COVID-19 [48]. 
One of the biggest concerns lies around AGPs during resuscitation. The current position of RCUK is 
that chest compressions alone are an AGP and staff should wear level 3 PPE for AGPs; while the 
current PHE guidance explicitly stated that chest compression and defibrillation are not AGPs. 
International guidelines currently list CPR as an AGP but they do not universally make clear which 
steps of the CPR process (e.g., defibrillation, chest compression, airway and ventilation) are AGPs. 
With the continued escalation of COVID-19, guidelines and protocols will continue to be updated in 
response to ever-growing research, experience and clinical trials. During such uncertain times, it 
remains the clinician’s responsibility to deliver the best care within their remit but also to do so 
within personal safety parameters.  
Stress management and wellbeing  
As noted within this article, the pandemic brings with it new clinical challenges and requires 
ambulance clinicians to work and think differently about their practice. Combined with a potential 
increase in attendance to seriously unwell, dying and deceased patients as the contagion reaches its 
peak, paramedics are likely to find themselves having to make critical clinical decisions which are 
both ethically and morally challenging to their professional practice [49], and which may be opposing 
to their own personally held values and beliefs. This may result in ‘moral injury’ [50] whereby 
individuals experience thoughts relating to themselves and/or others which are negative and critical 
(such as thinking that they have failed a patient or not provided the care which they know a patient 
would have received under ‘normal’ circumstances). This may lead to feelings of intense guilt, shame 
and/or blame [51]. These thoughts may become injurious due to the longer-term impact upon an 
individual’s mental wellbeing in terms of the development of distress, anxiety, depression, post-
traumatic stress and potentially suicidal ideation [52].  
The uncertainty and severity of the epidemiological progression of the disease will naturally result in 
individuals feeling extremely conflicted in their roles as healthcare professionals, and in their ‘roles’ 
in personal life such as son, daughter, husband, wife... The psychological impact that this has can be 
profound. In particular, this will likely include heightened emotional and behavioural responses to 
potential pathogenic exposure including extreme fear and anxiety at risk of infection of self and 
others, and intense feelings relating to a perceived elevated risk of mortality.  
Along with shift working, exhaustion and fatigue, limited time for rest and to eat nutritious meals, 
and with the challenges of physical distancing and social isolation which may be impacting upon 
family life, it potentially makes for an extremely distressing and psychologically traumatic time.  
Feeling scared and fearful at the risk of uncertainty is a very difficult thing to sit with; we usually like 
some kind of order and ‘normality’ to our lives, and this is currently being challenged. To feel this 
way however, is a normal human response to a situation which is far from normal [53].  
Whilst many people are likely to experience distress at some point, if not throughout the pandemic, 
some individuals may also experience a hopeful outlook with an increased sense of personal 
strength which enhances feelings of resilience [54]. As they appraise the impact of this viral disease 
in terms of their own beliefs and values, it brings with it, existential considerations and thoughts 
which lead to a changed perception of life with new priorities and more meaningful personal 
relationships which can bring enhanced psychological wellbeing [55].  
Importantly, connecting and talking with others is something which is so fundamental, yet can 
provide much needed offloading of distressing and overwhelming thoughts, normalise feelings, and 
as research studies have highlighted, is key to the healing process. Feeling supported and cared for, 
and experiencing kindness and compassion, enhances wellbeing, promotes recovery and protects 
mental health [56].  
As we move through the pandemic to the peak of contagion and in the days and months afterwards, 
it is human connectivity and the support of each other that will enable all to come through this time 
of adversity, adapt to the new normality of life, work, and the better times to come.  
Conclusion  
The authors would like to thank the numerous paramedics who have asked them for information 
about various aspects of COVID-19 which lead to the different sections and the rapid production of 
this article. We hope this article is useful in answering these queries and in supporting paramedics in 
their practice during these challenging times.  
Finally, we also offer a disclaimer that while the the information and advice provided within this 
article is the most up-to-date currently (7th April 2020). This is a rapidly changing field with the 
evidence base being added to daily (as evidenced by the multiple rewrites of this article within the 
past week!), therefore it is important that Paramedics keep up to date with the latest clinical 
guidance from their employers.  
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